Episode 1 – Dr Sri Gopal, Janssen Pharmaceuticals
Posted: 26 March 2021 | Drug Target Review | 1 comment
Listen along to learn more about drug development for schizophrenia from Dr Sri Gopal, Head of Psychiatry R&D for Janssen!
In this episode, DTR’s Assistant Editor, Hannah Balfour, discusses the development of treatments for schizophrenia with Dr Sri Gopal, the Head of Psychiatry research and development for the Neuroscience Therapeutic Area at Janssen Pharmaceuticals. They also explore some of the most exciting developments in the field, Janssen’s schizophrenia R&D focus, the knowledge gaps that Dr Gopal believes are key to developing more effective therapies and so much more!
Let us know what you think of the episode in the comments below – if you liked this episode, stay tuned, our next one is coming soon!
Related topics
Disease research, Drug Development, Drug Discovery, Drug Targets, Genetic analysis, Genomics, In Vivo, Therapeutics
Related conditions
Schizophrenia
Related organisations
Janssen Pharmaceuticals
Related people
Dr Sri Gopal (Janssen Pharmaceuticals)
I wish he would of gone more into detail on the newer medicines being developed like Karxt or Sep-363856 that promise to alleviate a lot of the side effects from current treatments and are giving a lot of hope to a lot of people right now. Other then that it was good